UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Parallel Accumulation of Tumor Hyaluronan, Collagen, and Other Drivers of Tumor Progression

Clinical cancer research, 2018-10, Vol.24 (19), p.4798-4807

2018

Volltextzugriff (PDF)

Pharmacokinetics of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Locally Advanced or Metastatic Solid Tumors: the Role of Alpha-1-Acid Glycoprotein Binding

Clinical cancer research, 2011-04, Vol.17 (8), p.2512-2520

2011

Volltextzugriff (PDF)

Phase I and Pharmacokinetics Trial of ABI-007, a Novel Nanoparticle Formulation of Paclitaxel in Patients With Advanced Nonhematologic Malignancies

Journal of clinical oncology, 2005-11, Vol.23 (31), p.7785-7793

2005

Volltextzugriff (PDF)

Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies

Journal of clinical oncology, 2001-07, Vol.19 (13), p.3267-3279

2001

Volltextzugriff (PDF)

Ras Protein Farnesyltransferase: A Strategic Target for Anticancer Therapeutic Development

Journal of clinical oncology, 1999-11, Vol.17 (11), p.3631-3652

1999

Volltextzugriff (PDF)

Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray

Cancer research (Chicago, Ill.), 2002-05, Vol.62 (10), p.2890-2896

2002

Volltextzugriff (PDF)

PRL phosphatases as potential molecular targets in cancer

Molecular cancer therapeutics, 2005-11, Vol.4 (11), p.1653-1661

2005

Volltextzugriff (PDF)

The cationic porphyrin TMPyP4 down-regulates c-MYC and human telomerase reverse transcriptase expression and inhibits tumor growth in vivo

Molecular cancer therapeutics, 2002-06, Vol.1 (8), p.565-573

2002

Volltextzugriff (PDF)

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

Journal of clinical oncology, 1997-06, Vol.15 (6), p.2403-2413

1997

Volltextzugriff (PDF)

ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents

Nature medicine, 1997-06, Vol.3 (6), p.639-645

1997

Volltextzugriff (PDF)

American Society of Clinical Oncology Technology Assessment: Chemotherapy Sensitivity and Resistance Assays

Journal of clinical oncology, 2004-09, Vol.22 (17), p.3631-3638

2004

Volltextzugriff (PDF)

Drug Targeting of the c-MYC Promoter to Repress Gene Expression via a G-Quadruplex Silencer Element

Seminars in oncology, 2006-08, Vol.33 (4), p.498-512

2006

Volltextzugriff (PDF)

A Phase I Study of Onyx-015, an E1B Attenuated Adenovirus, Administered Intratumorally to Patients with Recurrent Head and Neck Cancer

Clinical cancer research, 2000-03, Vol.6 (3), p.798

2000

Volltextzugriff (PDF)

Effects of cationic porphyrins as G-quadruplex interactive agents in human tumor cells

Cancer research (Chicago, Ill.), 1999-02, Vol.59 (3), p.639-644

1999

Volltextzugriff (PDF)

Targeting Aurora-2 kinase in cancer

Molecular cancer therapeutics, 2003-06, Vol.2 (6), p.589-595

2003

Volltextzugriff (PDF)

Does intraosseous equal intravenous? A pharmacokinetic study

The American journal of emergency medicine, 2008, Vol.26 (1), p.31-38

2008

Volltextzugriff (PDF)

There are no bad anticancer agents, only bad clinical trial designs--twenty-first Richard and Hinda Rosenthal Foundation Award Lecture

Clinical cancer research, 1998-05, Vol.4 (5), p.1079-1086

VON HOFF, D. D

1998

Volltextzugriff (PDF)

Identification of human polo-like kinase 1 as a potential therapeutic target in pancreatic cancer

Molecular cancer therapeutics, 2004-05, Vol.3 (5), p.641-646

2004

Volltextzugriff (PDF)

selection of Cancer Chemotherapy for a Patient by an In Vitro Assay Versus a Clinician

JNCI : Journal of the National Cancer Institute, 1990-01, Vol.82 (2), p.110-116

1990

Volltextzugriff (PDF)

G-quadruplexes as targets for drug design

Pharmacology & therapeutics (Oxford), 2000-03, Vol.85 (3), p.141-158

2000

Volltextzugriff (PDF)

The mitotic serine threonine kinase, Aurora-2, is a potential target for drug development in human pancreatic cancer

Molecular cancer therapeutics, 2004-04, Vol.3 (4), p.451-457

2004

Volltextzugriff (PDF)

A phase I trial of topical topitriol (calcitriol, 1,25-dihydroxyvitamin D3) to prevent chemotherapy-induced alopecia

Anti-cancer drugs, 1999-04, Vol.10 (4), p.393-396

1999

Volltextzugriff (PDF)

A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer

Annals of oncology, 1996-04, Vol.7 (4), p.347-353

1996

Volltextzugriff (PDF)

Tubulin-Associated Drug Targets: Aurora Kinases, Polo-like Kinases, and Others

Seminars in oncology, 2006-08, Vol.33 (4), p.436-448

2006

Volltextzugriff (PDF)

Abstract PD1-3: Ph1b study of the PI3K inhibitor GDC-0032 in combination with fulvestrant in patients with hormone receptor-positive advanced breast cancer

Cancer research (Chicago, Ill.), 2013-12, Vol.73 (24_Supplement), p.PD1-3-PD1-3

2013

Volltextzugriff (PDF)

1 – 25 von 407

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(350)
Mit Volltextzugriff
(322)

Publikationsform

Sprache

Englisch
(406)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(388)
Life Sciences & Biomedicine
(381)
Humans
(369)
Oncology
(324)
Biological And Medical Sciences
(210)
Medical Sciences
(196)
Female
(181)
Pharmacology. Drug Treatments
(173)
Antineoplastic Agents
(168)
Male
(140)
Middle Aged
(138)
Adult
(131)
Chemotherapy
(131)
Aged
(126)
Neoplasms - Drug Therapy
(106)
Pharmacology & Pharmacy
(77)
Drug Evaluation
(66)
Dose-Response Relationship, Drug
(65)
Antineoplastic Agents - Therapeutic Use
(64)
Animals
(61)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Cancer Research
(37)
Cancer Treatment Reports
(34)
Anti-Cancer Drugs
(30)
Journal Of Clinical Oncology
(29)
Investigational New Drugs
(27)
Clinical Cancer Research
(25)
Annals Of Oncology
(16)
Cancer
(14)
Seminars In Oncology
(14)
Jnci : Journal Of The National Cancer Institute
(12)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Parallel Accumulation of Tumor Hyaluronan, Collagen, and Other Drivers of Tumor Progression

Pharmacokinetics of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Locally Advanced or Metastatic Solid Tumors: the Role of Alpha-1-Acid Glycoprotein Binding

Phase I and Pharmacokinetics Trial of ABI-007, a Novel Nanoparticle Formulation of Paclitaxel in Patients With Advanced Nonhematologic Malignancies

Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies

Ras Protein Farnesyltransferase: A Strategic Target for Anticancer Therapeutic Development

Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray

PRL phosphatases as potential molecular targets in cancer

The cationic porphyrin TMPyP4 down-regulates c-MYC and human telomerase reverse transcriptase expression and inhibits tumor growth in vivo

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents

American Society of Clinical Oncology Technology Assessment: Chemotherapy Sensitivity and Resistance Assays

Drug Targeting of the c-MYC Promoter to Repress Gene Expression via a G-Quadruplex Silencer Element

A Phase I Study of Onyx-015, an E1B Attenuated Adenovirus, Administered Intratumorally to Patients with Recurrent Head and Neck Cancer

Effects of cationic porphyrins as G-quadruplex interactive agents in human tumor cells

Targeting Aurora-2 kinase in cancer

Does intraosseous equal intravenous? A pharmacokinetic study

There are no bad anticancer agents, only bad clinical trial designs--twenty-first Richard and Hinda Rosenthal Foundation Award Lecture

Identification of human polo-like kinase 1 as a potential therapeutic target in pancreatic cancer

selection of Cancer Chemotherapy for a Patient by an In Vitro Assay Versus a Clinician

G-quadruplexes as targets for drug design

The mitotic serine threonine kinase, Aurora-2, is a potential target for drug development in human pancreatic cancer

A phase I trial of topical topitriol (calcitriol, 1,25-dihydroxyvitamin D3) to prevent chemotherapy-induced alopecia

A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer

Tubulin-Associated Drug Targets: Aurora Kinases, Polo-like Kinases, and Others

Abstract PD1-3: Ph1b study of the PI3K inhibitor GDC-0032 in combination with fulvestrant in patients with hormone receptor-positive advanced breast cancer

Suchergebnisse filtern